Precision BioSciences, Inc. (DTIL)
DTILNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$6.90
-0.3800 (-5.22%) today
Regular session, Nov 17, 10:47 AM ET
- Market cap
- $263.08m
- P/E
- –
- EPS, last 4 quarters
- $-1.34
- Dividend yield
- –
- Day range
- $6.90 to $7.46
- 52-week range
- $3.53 to $11.29
- Average volume
- –
- Previous close
- $7.28
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $40.00, +479.7% from here
Earnings
next estimate $-0.9000Next report
Dec 2025
+271.4%
Mar 2026
-25.9%
Jun 2026
+4.0%
Sep 2026
+36.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $34.20m | $10.84m | – | – |
| Gross profit | $34.20m | $10.84m | – | – |
| Operating income | $12.51m | -$9.07m | -$19.16m | -$20.43m |
| Net income | $20.13m | -$18.44m | -$32.65m | -$7.59m |
News
8 latest- Precision BioSciences, Inc. Projects Cash Runway into Fourth Quarter of 2029Fintel · Nov 9, 2026
- Precision BioSciences, Inc. Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsFintel · Nov 6, 2026
- Precision BioSciences Prices $125 Mln Underwritten Offering To Fund Gene-Editing Programs RTTNews · Nov 6, 2026
- Precision BioSciences, Inc. Announces PBGENE-HBV Phase 2 Advancement and PBGENE-DMD Safety UpdateFintel · Nov 5, 2026
- Precision BioSciences, Inc. Reports Third Quarter 2026 Financial ResultsFintel · Nov 3, 2026
- Precision Biosciences is Now Oversold (DTIL)BNK Invest · Oct 6, 2026
- Precision BioSciences Doses First Patient In Phase 1/2 Of PBGENE-DMD In Duchenne Muscular Dystrophy RTTNews · Aug 24, 2026
- Precision BioSciences Posts Q2 Loss; PBGENE-HBV Delivers Clinical CccDNA Elimination Data RTTNews · Aug 20, 2026
The company
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Precision's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- precisionbiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.